Klothea Bio is a preclinical biotechnology company focused on developing next-generation longevity therapeutics designed to delay age-related diseases. Its lead program leverages proprietary mRNA technology to enhance the endogenous secretion of the Klotho protein—a pleiotropic protein that may offer benefits across various organ systems, including the brain, heart, kidneys, lungs, and bones. By restoring the Klotho levels that decrease due to aging, disease, or genetic factors, Klothea aims to unlock a new therapeutic pathway to improve health span. The company is preparing for Phase 1 clinical trials in early 2026, with metabolic syndrome identified as the first planned indication. Additionally, Klothea is proud to partner with the Healthy Longevity clinic, which has been selected as a semifinalist in the $101 million XPRIZE Healthspan competition for its innovative approach to enhancing health span using our proprietary Klotho mRNA therapy.
Klothea Bio is a preclinical biotechnology company focused on developing next-generation longevity therapeutics designed to delay age-related diseases. Its lead program leverages proprietary mRNA technology to enhance the endogenous secretion of the Klotho protein—a pleiotropic protein that may offer benefits across various organ systems, including the brain, heart, kidneys, lungs, and bones. By restoring the Klotho levels that decrease due to aging, disease, or genetic factors, Klothea aims to unlock a new therapeutic pathway to improve health span. The company is preparing for Phase 1 clinical trials in early 2026, with metabolic syndrome identified as the first planned indication. Additionally, Klothea is proud to partner with the Healthy Longevity clinic, which has been selected as a semifinalist in the $101 million XPRIZE Healthspan competition for its innovative approach to enhancing health span using our proprietary Klotho mRNA therapy.
A healthy lifestyle and regular exercise can help increase Klotho protein levels by a few dozen pg/mL. However, these practices may not sufficiently address the deficit of hundreds of pg/mL that many people experience, which is linked to age-related diseases.
Directly injecting the Klotho protein, similar to insulin administration, has not proven effective outside of laboratory settings.
Gene modification does show promise (and our team has worked on it), but it is an irreversible process that is nearly impossible to modulate. Additionally, viral vectors such as AAVs have caused severe adverse events in humans during other gene therapy programs.
Consequently, our team has focused on utilizing:
- mRNA technology to trigger an adjustable and reversible secretion of the Klotho protein. Our proprietary mRNA, inspired by natural human mRNA, is significantly more effective.
- Safe nanocarriers, designed for repeated use several times a year, as lipid nanoparticles like those used in Covid-19 mRNA vaccines are too immunogenic for safe application.
Robust intellectual property is protecting these innovative components. We are also evaluating other delivery methods, such as extracellular vesicles (exosomes), to further enhance our approach.
A healthy lifestyle and regular exercise can help increase Klotho protein levels by a few dozen pg/mL. However, these practices may not sufficiently address the deficit of hundreds of pg/mL that many people experience, which is linked to age-related diseases.
Directly injecting the Klotho protein, similar to insulin administration, has not proven effective outside of laboratory settings.
Gene modification does show promise (and our team has worked on it), but it is an irreversible process that is nearly impossible to modulate. Additionally, viral vectors such as AAVs have caused severe adverse events in humans during other gene therapy programs.
Consequently, our team has focused on utilizing:
- mRNA technology to trigger an adjustable and reversible secretion of the Klotho protein. Our proprietary mRNA, inspired by natural human mRNA, is significantly more effective.
- Safe nanocarriers, designed for repeated use several times a year, as lipid nanoparticles like those used in Covid-19 mRNA vaccines are too immunogenic for safe application.
Robust intellectual property is protecting these innovative components. We are also evaluating other delivery methods, such as extracellular vesicles (exosomes), to further enhance our approach.
Klothea Bio is a preclinical biotechnology company focused on developing next-generation longevity therapeutics designed to delay age-related diseases. Its lead program leverages proprietary mRNA technology to enhance the endogenous secretion of the Klotho protein—a pleiotropic protein that may offer benefits across various organ systems,
Klothea Bio is a preclinical biotechnology company focused on developing next-generation longevity therapeutics designed to delay age-related diseases. Its lead program leverages proprietary mRNA technology to enhance the endogenous secretion of the Klotho protein—a pleiotropic protein that may offer benefits across various organ systems, including the brain, heart, kidneys, lungs, and bones. By restoring the Klotho levels that decrease due to aging, disease, or genetic factors, Klothea aims to unlock a new therapeutic pathway to improve health span. The company is preparing for Phase 1 clinical trials in early 2026, with metabolic syndrome identified as the first planned indication. Additionally, Klothea is proud to partner with the Healthy Longevity clinic, which has been selected as a semifinalist in the $101 million XPRIZE Healthspan competition for its innovative approach to enhancing health span using our proprietary Klotho mRNA therapy.
The Chief Science Officer plays a crucial role in researching age-related diseases, particularly through the lens of innovative advancements such as the Klotho protein and mRNA technology.
As an mRNA expert, I focus on the potential of mRNA technology to combat age-related diseases, particularly through the study of the Klotho protein, which plays a crucial role in aging and longevity.
As a biopharma expert, William Haseltine focuses on innovative solutions for age-related diseases, including research on the Klotho protein and advancements in mRNA technology. For more insights, visit https://www.williamhaseltine.com/
195 NW 40th Street, Miami, FL 33127
